| Species Reactivity | Human |
| Clone | 3D1 |
| Source/Isotype | Human IgG1, Kappa |
| Application | Flow Cytometry |
| Target | Detects MUC1 |
| Gene | MUC1 |
| Other Names | Mucin 1, CD227, EMA, H23AG |
| Gene ID | 4582 (Human) |
| Background | The research value of MUC1 stems from its role as a tumor-associated antigen aberrantly overexpressed and hypoglycosylated across a broad spectrum of epithelial cancers, including breast, lung, pancreatic, and ovarian malignancies. As a transmembrane glycoprotein that activates oncogenic pathways and promotes immune suppression by upregulating PD-L1 expression, MUC1 represents an ideal pan-cancer target with limited expression in normal tissues. Targeting MUC1 via diverse modalities-monoclonal antibodies, antibody-drug conjugates, bispecific NK cell engagers, CAR-T/NK cell therapies, and glycopeptide vaccines-offers a versatile therapeutic platform. Recent clinical advances, including promising phase I/II data for MUC1-targeted ADCs and dual-targeted CAR-NK strategies in solid tumors, underscore the transformative potential of anti-MUC1 interventions in reshaping the landscape of precision oncology. |
| Storage | Store at 2-8℃ short term (1-2 weeks).Store at ≤ -20℃ long term. Avoid repeated freeze-thaw. |
| Formulation | Supplied as a 0.2 μm filtered solution of PBS, pH7.2-7.4. |
| Endotoxin | < 1 EU/mg, determined by LAL gel clotting assay |
| Species Reactivity | Human |
| Clone | 3D1 |
| Source/Isotype | Human IgG1, Kappa |
| Application | Flow Cytometry |
| Target | Detects MUC1 |
| Gene | MUC1 |
| Other Names | Mucin 1, CD227, EMA, H23AG |
| Gene ID | 4582 (Human) |
| Background | The research value of MUC1 stems from its role as a tumor-associated antigen aberrantly overexpressed and hypoglycosylated across a broad spectrum of epithelial cancers, including breast, lung, pancreatic, and ovarian malignancies. As a transmembrane glycoprotein that activates oncogenic pathways and promotes immune suppression by upregulating PD-L1 expression, MUC1 represents an ideal pan-cancer target with limited expression in normal tissues. Targeting MUC1 via diverse modalities-monoclonal antibodies, antibody-drug conjugates, bispecific NK cell engagers, CAR-T/NK cell therapies, and glycopeptide vaccines-offers a versatile therapeutic platform. Recent clinical advances, including promising phase I/II data for MUC1-targeted ADCs and dual-targeted CAR-NK strategies in solid tumors, underscore the transformative potential of anti-MUC1 interventions in reshaping the landscape of precision oncology. |
| Storage | Store at 2-8℃ short term (1-2 weeks).Store at ≤ -20℃ long term. Avoid repeated freeze-thaw. |
| Formulation | Supplied as a 0.2 μm filtered solution of PBS, pH7.2-7.4. |
| Endotoxin | < 1 EU/mg, determined by LAL gel clotting assay |
